Servier Presents Long-Term INDIGO Analyses Demonstrating Sustained Clinical Benefit of VORANIGO® (vorasidenib) in IDH-Mutant Glioma Across Subgroups at SNO 2026

On November 17, 2026 Servier reported extended follow-up results and subgroup analyses from the Phase 3 INDIGO trial evaluating VORANIGO (vorasidenib) in mutant isocitrate dehydrogenase 1 or 2 (IDH1/2) glioma who received treatment following surgery as their primary therapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia. These analyses provide longer-term insights into VORANIGO’s clinical benefit across evaluated subgroups. Alongside these data, an exploratory analysis of seizure activity and quality of life among INDIGO patients was also presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The updated Phase 3 INDIGO results include analyses of 144 of 163 patients randomized to placebo who crossed over to VORANIGO from placebo by the January 17, 2025 data cutoff, along with analyses by histology in oligodendroglioma and astrocytoma. These results build on findings previously reported at ASCO (Free ASCO Whitepaper), which demonstrated continued benefit in progression-free survival (PFS) at a median follow-up time of 41.6 months.

"The results from the INDIGO analyses presented at SNO reinforce the clinical benefit of VORANIGO in patients with Grade 2 IDH-mutant glioma, with the crossover patient population data demonstrating consistent results," said Islam Hassan, M.D., MSc., Global Head of Development, Neuro-Oncology at Servier. "Together with the data on VORANIGO’s impact on quality of life, these findings strengthen our understanding of the impact of VORANIGO over time and underscore its important role in glioma care."

Efficacy data and subgroup analyses after extended follow-up with vorasidenib in INDIGO – a global, randomized, placebo-controlled, double-blinded, Phase 3 trial in grade 2 mutant isocitrate dehydrogenase 1/2 (mIDH1/2) glioma — November 14, 5:00–5:07 p.m. EST

The latest results from this analysis were presented by Timothy F. Cloughesy, M.D., David Geffen School of Medicine, Department of Neurology, University of California, Los Angeles, an investigator for the INDIGO trial. These data showed clinical benefit among patients who crossed over from placebo and across subgroups defined by histologic subtype. Key findings include:

Among patients who crossed over to VORANIGO, median PFS per investigator was 37.2 months overall (95% CI, 33.4-not estimable [NE]). Among patients with astrocytoma who crossed over, median PFS by investigator was 37.2 months (95% CI, 25.6-NE) and in patients with oligodendroglioma who crossed over, median PFS by investigator was not reached (95% CI, 24.6-NE). Median PFS per investigator was 33.4 months (95% CI, 24.6 months-NE) for patients with progressive disease (PD) at crossover and was NE for patients with no PD at crossover.
In a post-hoc analysis of patients who crossed over to VORANIGO from placebo, VORANIGO reversed average tumor growth; tumor volume increased on average by 16.1% per six months before crossover and decreased on average by 2.9% per six months after crossover. The shift from growth to shrinkage was observed in both oligodendroglioma and astrocytoma subgroups.
The substantial increase in objective response rate (ORR) by blinded independent review committee (BIRC) over time for the overall population (from 10.7% [95% CI, 6.5%–16.4%] in September 2022 to 20.8% [95% CI, 15.0%–27.8%] in January 2025) is reflected in patients with astrocytoma (increase from 7.5% [95% CI, 2.8%–15.6%] to 17.5% [95% CI, 9.9%–27.6%]) as well as those with oligodendroglioma (increased from 13.6% [95% CI, 17.2 %-22.6%] to 23.9% [95%, CI, 15.4%–34.1%]).
The safety profile remained consistent with previous data cutoffs with no new safety signals identified during extended follow-up or in crossover patients. Grade >3 treatment-emergent adverse events (TEAEs) occurred in 31.7% of patients randomized to VORANIGO and 20.1% of those crossed over from placebo. The most commonly reported Grade >3 TEAEs were increased alanine aminotransferase (10.8% and 7.6%), increased aspartate aminotransferase (4.8% and 3.5%), seizure (4.8% and 4.2%) and increased gamma-glutamyltransferase (GGT; 3% and 0.7%). There were no treatment-related deaths in either group, and TEAEs leading to discontinuation were uncommon among patients randomized to VORANIGO (4.8%) and those who crossed over from placebo (2.1%).
"Longer follow-up from INDIGO continues to demonstrate the durable clinical benefit of IDH-inhibition for patients with Grade 2 IDH-mutant glioma across patient subgroups," said Dr. Timothy Cloughesy. "These findings also show promising results in patients who crossed over from placebo, including those whose disease had already progressed, providing further insight into the potential role of IDH inhibition to help manage disease over time."

Impact of vorasidenib vs placebo on seizure rates and quality of life: exploratory analysis from Phase 3 INDIGO study — November 15, 11:07–11:14 a.m. EST

An exploratory analysis presented as an encore by Wolfgang Wick, M.D., Universitätsklinikum Heidelberg & German Cancer Research Center, examined seizure activity and quality of life in INDIGO participants who experienced at least one seizure in the baseline and/or on-treatment periods. At the January 17, 2025, data cutoff:

In the overall population of patients treated with VORANIGO, the proportion of patients with on-treatment seizures remained stable from March 2023 to January 2025 (98.1% vs 98.2%). Moreover, the seizure rate with VORANIGO decreased from 18.2 (95% CI, 8.4–39.5) to 15.9 (95% CI, 9.1–27.1) seizures per person-year between March 2023 and January 2025.
The rate ratio versus placebo improved from 0.36 (95% CI, 0.14–0.89; P=0.0263) to 0.28 (95% CI, 0.14–0.55; P=0.0002), supporting a sustained treatment effect with longer follow-up.
VORANIGO was associated with long-term stabilization of seizure frequency overall and across both oligodendroglioma and astrocytoma. Patients with oligodendroglioma treated with VORANIGO showed a trend towards low, stable seizure counts and patients with astrocytoma experienced low seizure counts regardless of treatment.
VORANIGO was associated with sustained preservation of quality of life, with exploratory analyses in patients with >1 seizure, showing a lower risk of worsening versus placebo on the Functional Assessment of Cancer Therapy–Brain (FACT-Br) scale (HR=0.38; 95% CI, 0.15–1.00) and its brain cancer subscale (HR=0.32; 95% CI, 0.11–0.91).

(Press release, Servier, NOV 17, 2026, View Source [SID1234674883])